Uneedle specializes in advanced microneedle technologies for intradermal and suprachoroidal administration, focusing on enhancing the delivery of therapeutic agents such as vaccines and biologics. Their lead product, Bella-mu, features ultra-short, sharp intradermic needles designed for easy and reliable injections, significantly reducing pain and anxiety associated with traditional needles. This innovative approach allows for precise delivery of up to 1 mL of fluid, making it particularly beneficial for cancer vaccine development and other therapeutic applications. The Bella-mu technology has demonstrated dose-sparing capabilities, which can enhance vaccine efficacy and availability, especially in urgent situations like viral outbreaks.

In addition to intradermal applications, Uneedle's Bella-Vue product facilitates suprachoroidal injections, targeting the back of the eye for conditions such as age-related macular degeneration and diabetic retinopathy. The company is committed to high-quality manufacturing, holding ISO13485 certification and utilizing proprietary semiconductor processes in their GMP-compliant facility in the Netherlands. Their collaborative efforts with academic and industry partners aim to further develop and optimize their microneedle technologies, ensuring they meet both customer and regulatory requirements while advancing the field of medical technology.

Netherlands

Uneedle realises a proprietary microneedle platform "Bella-mu" and "Bella-Vue", co-developing intradermal & suprachoroidal administered medicinal products with pharmaceutical partners.

Uneedle is the legal manufacturer of this superior - short lumen - delivery platform. The single, hollow "Uneedles" are FDA approved and CE marked for direct application in the clinics worldwide.

Uneedle

Company Details